Home Quality Improvement COVID-19 & CVD QI Programme Introduction COVID-19 QI Programme Module 2 Module 2: Patient identification and activation This programme has been funded by Pfizer Ltd. Pfizer were not involved in the development of the programme, content, selection of speakers or their arrangements. All content has been independently developed by the PCCS. The information provided in this presentation is for educational purposes only. Prescribing or management decisions made by clinicians are exclusively their own responsibility. The speaker/PCCS bear no responsibility regarding management or prescribing decisions made by others, or otherwise. Downloadable Slides Please click here to view Resources and Useful Links PCCS COVID-19 Care Plan Downloadable PDF NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 NHS Health Check Ready for Module 3 Quality Improvement Programme COVID-19 & CVD QI Programme IntroductionModule 1Module 2Module 3CKD QI Programme IntroductionModule 1Module 2Module 3Module 4Lipid QI ProgrammeModule 1 Module 2Module 3 Module 4 Additional ResourcesHeart Failure QI ProgrammeOberoi Disease Management Digital Audit Platform Explore PCCS Member Benefits